Publication:
The synergetic effect of edaravone and scutellarin in the MPP(+)-induced cell model of Parkinson's disease

Simple item page
dc.contributor.authorWei Wei
dc.contributor.authorWu Jing
dc.contributor.authorZhang Dandan
dc.contributor.authorXu Shoucheng
dc.contributor.authorWang Yi
dc.contributor.authorLi Xuezhong
dc.contributor.authorYu Ming
dc.contributor.authorChen Xiaopeng
dc.contributor.departmentBiología Celular e Histología
dc.coverage.spatial, , , ,
dc.date.accessioned2025-10-13T11:52:24Z
dc.date.available2025-10-13T11:52:24Z
dc.date.issued2025
dc.description.abstractParkinson's disease (PD) is a limb movement disorder caused by the degeneration of brain neurons and seriously affects the quality of life of the elderly. However, the current drugs are symptomatic treatments that cannot prevent or delay the development of the disease. Targeted therapy for pathogenesis may be the direction of development in the future. Oxidative stress and the inflammatory response are involved in the pathogenesis of PD. Edaravone and scutellarin have been studied in antioxidant and anti-inflammatory reactions. The focus of this study is whether there is synergy between the two and its mechanism. Through research, we found that edaravone and scutellarin at different dose combinations have synergistic effects in 1-methyl-4-phenylpyridinium (MPP+)-induced PC12 cells using the Chou-Talalay joint index method. According to the CompuSyn software calculation, the results showed that the combination index (CI) of the combined application of 15 μM edaravone and 15 μM scutellarin was the lowest, indicating that the synergistic effect was the best. Compared with the single drug, the synergy increased superoxide dismutase (SOD) and reduced glutathione (GSH) levels, reduced the levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and enhanced the anti-apoptosis ability in the MPP(+) induced cell model of PD.
dc.formatapplication/pdf
dc.format.extent10
dc.identifier.citationHistology and Histopathology, Volúmen 40, nº 9 (2025)
dc.identifier.doihttps://doi.org/10.14670/HH-18-874
dc.identifier.eissn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/166130
dc.languageeng
dc.publisherUniversidad de Murcia, Departamento Histología e Histopatología
dc.relationSin financiación externa a la Universidad
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEdaravone
dc.subjectScutellarin
dc.subjectParkinson's disease
dc.subjectSynergetic
dc.subjectOxidative stress
dc.subject.odsNo relacionado con ningún objetivo de desarrollo sostenible
dc.titleThe synergetic effect of edaravone and scutellarin in the MPP(+)-induced cell model of Parkinson's disease
dc.typeinfo:eu-repo/semantics/article
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Wei-40-1457-1466-2025.pdf
Size:
9.26 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.40, nº9 (2025)